iShares iBoxx $ Inv Grade Corporate Bond ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.65 (market cap $2.27B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 12.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | SLS | |
|---|---|---|
Market Cap | $28.50B | $2.27B |
Volume | 37,320,110 | 4,179,659 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $15.46 |
52-Week Low | $101.83 | $1.39 |
Typical Hold Time | 125 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.47 with a slight 0.34% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September 2026 and concerns about rising Treasury yields impacting investment-grade corporate bonds.
The outlook remains cautious as rising interest rates pressure bond ETFs, though LQD's 4.8% yield and high-quality portfolio provide some stability. Key risks include further bond market volatility and economic uncertainty, while institutional activity shows mixed sentiment with elevated short positions.
No Aura AI signal available yet.
Trailing returns across standard periods
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →